The data presented at the International Congress also supported the safety of the plaque excision procedure. There were no major complications. Minor complications noted were low (4.4%). In the majority of the patients Jordan Cap Gray
The patients reported on today were treated for blockages located in the arteries above the knee, and were among those with severest cases of PAD. Over 37% of the patients had extreme rest pain and actual tissue decay on their legs and/or feet. Additionally, 77% percent of the blockages treated (known as "lesions"), were classified as B, C or D in the TASC classification system established by the TransAtlantic Inter Society Consensus Group. New Era Snapbacks Uk TASC B, C and D categories describe lesions that can be the most difficult to treat.
Peripheral arterial disease (or PAD) is a condition that afflicts an estimated 12 million Americans. It occurs when plaque accumulates in the arteries and blocks blood flow in the legs. These blockages can result in severe leg pain, very limited physical mobility and ultimately, can lead to amputation. The SilverHawk System is a minimally invasive method of removing the obstructive plaque and restoring blood flow to the legs and feet.
(1) J Endovas Ther 2004; 11(suppl II): II 107 II 127; Bates and AbuRahma,(2) J Vasc Surg, TransAtlantic Inter Society Consensus, Jan 2000Duke Rohlen Leslie Trigg
cannot provide any assurance that the clinical results announced above will be replicated at other hospitals in the future. FoxHollow develops and markets minimally invasive plaque excision devices for the treatment of peripheral artery disease (PAD). are thought to suffer from PAD with 2.5 million patients currently diagnosed. PAD results from plaque that accumulates in the arteries and blocks blood flow in the legs. These blockages can result in severe pain for patients and very limited physical mobility. The SilverHawk System is a minimally invasive method of removing the obstructive plaque and restoring blood flow to the legs and feet.
PHOENIX, Feb. 14 /PRNewswire FirstCall/ The first one year clinical data on the SilverHawk(TM) Plaque Excision System was presented today at the Arizona Heart International Congress XVIII. Dr. Venkatesh Ramaiah, a vascular surgeon at the Arizona Heart Hospital, reported an 86% clinical patency rate for 104 patients with peripheral arterial disease who were treated with SilverHawk and followed for 12 months.
"What is especially noteworthy about this data is how closely the 12 month outcomes mirror the 6 month outcomes reported in a multi center Adidas Cap Womens White
Earlier this year, a non randomized, multi center outcomes registry on SilverHawk (the TALON study) showed a 6 month clinical patency rate of 89% for 160 patients treated with 317 lesions (blockages) anywhere in the leg. Clinical patency here refers to the percentage of lesions, which did not undergo a repeat revascularization procedure during the follow up period. In the TALON study, over a third of the treated limbs had critical limb ischemia, a limb threatening condition that often results in amputation.
1 Release One Year Clinical Data Air Jordans Hats
treated, SilverHawk was used as the only therapy. Stents were placed in just 8.6% of the cases.
Published one year patency rates for previous treatments for PAD range from approximately 60% to 81%. For example, peer reviewed published literature shows one year patency for surgical bypass at 77 81%.(1) Reported one year patency for angioplasty and stenting is 61% and 67% respectively.(2)
On SilverHawk Plaque Excision System Presented At Ari
outcomes study earlier this year. It shows that patients treated with SilverHawk are experiencing not only immediate relief from their symptoms, but durable relief as well," said Robert Thomas, president and chief executive officer of FoxHollow Technologies , which developed and manufactures the SilverHawk System.
Fox Hollow Technologies, Inc. Announces Pricing Of Initial Public Offering FDA Issues Alert For Preloaded Syringes.
"One of the reasons patients with PAD traditionally have been under diagnosed and under treated is due to a lack of durable treatment options. This data suggests we may finally have a better way to address this debilitating condition. We are very encouraged by the results," said Dr. Ramaiah.
Louis Vuitton Belt Women
Gucci Belt New Style
Nike Cap Sale
Ferragamo Belts White
New Era Ny Giants Hat
Cleveland Indians Caps
New Era Boston Bruins
New Era London
New Era Womens Caps
Nike Cap Original Vs Fake
Gucci Belt Drawing
Air Jordan Cap Space Jam
New Era Orioles Hat
Arizona Diamondbacks Hat Purple